Lab equipment
Kailos Iota™ Liquid Biopsy

Next Stage in Liquid Biopsy Technology

Kailos IotaTM combines TargetRichTM, our foundational genetic enrichment technology, with next-generation sequencing and statistical machine learning that results in a highly specific cancer assay of multiple solid tumors at all stages.

The Iota assay detects methylation differences in a person’s blood sample, the superior choice for early disease detection. The process of detecting these changes is called a methylated liquid biopsy and it can be used as a companion to standard imaging protocols such as mammograms and low dose CT scans among others. Because methylated liquid biopsies can be performed more frequently for screening, treatment and recurrence detection they are expected to improve patient outcomes and increase participation in screening programs.

What is Methylation?

Cytosine is one of the four bases that make up DNA. The addition of a methyl (CH3) group to the 5th atom in the ring turns it into 5-methylcytosine; this methylation of cytosine plays a role in regulating the expression of genes. For instance, when a gene’s promoter region is methylated, the expression level is often reduced. Kailos scientists evaluated thousands of pairs of samples with and without tumors to identify sites that are methylated differently between normal tissues and cancer.

Blue DNA
TargetRich Workflow

Our patented workflow is designed to capture the sites that are differentially methylated and separate them from all the rest of a person’s DNA. All of the non-informative regions are destroyed and, importantly, the methylation status of each of the key regions is preserved. These regions are deeply sequenced before our data analysis pipeline assesses quality, determines methylation and classifies the sample as indicative of a tumor or not.

Female patient with doctor
Clinical Studies

Along with our partners at world class hospital systems, Kailos Iota is entering the first phase of clinical performance evaluation with studies designed to show accuracy, sensitivity and specificity when compared to the current standards in cancer screening. We look forward to announcing these partners soon and sharing the results as well!

Interested in Learning More?


Please contact us below.

We look forward to hearing from you!

Get In Touch


601 Genome Way
Suite 2005
Huntsville, AL  35806


9am - 5pm (Central Time)


For technical inquiries